Covidien launches new endovascular CTO treatment devices

Covidien has announced the launch of its new Viance Crossing Catheter and Enteer Re-entry System in the US, Europe and other selected international markets.

The devices are specified for use in the endovascular treatment of chronic total occlusions (CTOs) and are designed to enable access to the distal end of a lesion, allowing physicians to treat even the most challenging CTOs through endovascular means.

According to the manufacturer, this allows surgeons to utilise skills and finesse rather than blunt force or more aggressive cutting, which can cause fine control to be compromised.

Other benefits include the distinctive shape of the re-entry balloon, which enables it to self-orient within the vessel and is unique among re-entry systems.

Brian Verrier, vice-president and general manager for Covidien's peripheral vascular division, said: "We strive to demonstrate our commitment to advancing the treatment of vascular disease worldwide by delivering innovation that achieves both clinical and economic value for our healthcare partners."

Last month, the company expanded its business capabilities through the launch of a new research and development facility in China.